[go: up one dir, main page]

MX9304878A - Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis. - Google Patents

Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.

Info

Publication number
MX9304878A
MX9304878A MX9304878A MX9304878A MX9304878A MX 9304878 A MX9304878 A MX 9304878A MX 9304878 A MX9304878 A MX 9304878A MX 9304878 A MX9304878 A MX 9304878A MX 9304878 A MX9304878 A MX 9304878A
Authority
MX
Mexico
Prior art keywords
azaspiran
substituted
psoriasis
manufacture
treatment
Prior art date
Application number
MX9304878A
Other languages
English (en)
Inventor
Alison Mary Badger
Don Edgar Griswold
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9304878A publication Critical patent/MX9304878A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Indole Compounds (AREA)

Abstract

Se describe un método para tratar psoriasis en un mamífero que requiere del mismo, que comprende administrar a dicho mamífero una cantidad efectiva de un azaspirano substituido.
MX9304878A 1992-08-13 1993-08-11 Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis. MX9304878A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929217116A GB9217116D0 (en) 1992-08-13 1992-08-13 Methods

Publications (1)

Publication Number Publication Date
MX9304878A true MX9304878A (es) 1994-05-31

Family

ID=10720232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304878A MX9304878A (es) 1992-08-13 1993-08-11 Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.

Country Status (12)

Country Link
US (1) US5981538A (es)
EP (1) EP0654996A4 (es)
JP (1) JPH08500120A (es)
KR (1) KR950702830A (es)
CN (1) CN1037815C (es)
AU (1) AU670970B2 (es)
CA (1) CA2142223A1 (es)
GB (1) GB9217116D0 (es)
MX (1) MX9304878A (es)
NZ (1) NZ255753A (es)
WO (1) WO1994004150A1 (es)
ZA (1) ZA935831B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9217121D0 (en) * 1992-08-13 1992-09-23 Smithkline Beecham Corp Methods
BR9601909A (pt) * 1995-07-13 1999-10-13 Smithkline Beecham Corp N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
IL118815A (en) * 1995-07-13 2000-06-29 Anormed Inc N,N-diethyl-8,8-dipropyl-2-azaspiro¬4.5¾decane-2-propanamine dimaleate and pharmaceutical compositions comprising it
US5843936A (en) * 1996-06-28 1998-12-01 Bernstein; Lawrence R. Topical administration of azaspiranes to prevent or treat skin conditions associated with hyperproliferation of keratinocytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
EP0542860B1 (en) * 1990-08-10 1998-05-20 AnorMED Inc Immunosuppressive compositions
AU652583B2 (en) * 1990-09-24 1994-09-01 Smithkline Beecham Corporation Methods

Also Published As

Publication number Publication date
CN1100932A (zh) 1995-04-05
US5981538A (en) 1999-11-09
JPH08500120A (ja) 1996-01-09
CA2142223A1 (en) 1994-03-03
ZA935831B (en) 1995-01-18
AU5010193A (en) 1994-03-15
CN1037815C (zh) 1998-03-25
EP0654996A1 (en) 1995-05-31
NZ255753A (en) 1999-06-29
AU670970B2 (en) 1996-08-08
WO1994004150A1 (en) 1994-03-03
KR950702830A (ko) 1995-08-23
GB9217116D0 (en) 1992-09-23
EP0654996A4 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
NO174764B (no) Fremgangsmåte for fremstilling av et preparat som er virksomt ved behandling av hyperkeratotiske og andre hudsykdommer
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
ES2157252T3 (es) Aplicacion del riluzol en el tratamiento del neuro-sida.
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
ES2121779T3 (es) Utilizacion de espiperona como agente inmunosupresor y antiinflamatorio.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ES2185655T3 (es) Fracciones de acido aurintricarboxilico y analogos con actividad anti-angiogenica y metodos de uso.
ES2139674T3 (es) Metodo para tratar la sintomatologia del sindrome premenstrual con vitamina d o vitamina d y calcio.
MX9304185A (es) Producto y composicion farmaceutica que lo contiene para el tratamiento de la mastitis y la mestritis bovina.
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
ES2064983T3 (es) Dispositivo para el tratamiento termico y/o humectacion de carretes, canillas y conos.
ES2125356T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 8.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
MX9206135A (es) Metodos
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees